Association between abnormal IMDC laboratory criteria after surgery and cancer-specific and overall survival in non-metastatic renal cell carcinoma: Potential biomarkers for adjuvant therapy patient selection.
Abstract
567 Background: The International Metastatic RCC Database Consortium (IMDC) criteria are widely used for risk stratification in metastatic renal cell carcinoma (RCC), but their role in non-metastatic RCC is less defined, especially as a biomarker of recurrence. This study seeks to evaluate (1) the prevalence of IMDC abnormalities in non-metastatic RCC patients (nmRCCC), (2) the impact of nephrectomy on the normalization of these criteria, and (3) the association between post-operative IMDC abnormalities and oncological outcomes. Methods: Data from the Canadian Kidney Cancer Information System (CKCis) were analyzed to identify non-metastatic RCC patients diagnosed between January 2011 and April 2024 who underwent nephrectomy after diagnosis. Laboratory tests were evaluated preoperatively (within 6 months before surgery) and postoperatively (between 2 and 15 months). Univariable and multivariable analyses were performed to assess the association with overall survival, recurrence-free survival, and cancer-specific survival. Results: A total of 1,804 patients were analyzed, with 65.7% male and mean age was 62.5y. Tumors pathological characteristics were: pT1 (69.2%), pT2 (5.6%), pT3 (1.8%), pT4 (0.28%); tumors necrosis (21.8%); mean tumor size (4.7cm) and clear cell carcinoma (73.1%). Preoperative hemoglobin (Hb), neutrophils, platelets (Plt), and corrected calcium (Ca 2+ ) IMDC criteria abnormalities were identified in 19.4, 9.6, 4.3, and 3.2% of patients, respectively. After surgery, 45.4, 79.8, 80.4, and 76.9% of these abnormal cases normalized, respectively. Among patients with normal preoperative Hb, neutrophils, Plt, and Ca 2+ , 9.65, 4.4, 1.0, and 1.6% developed postoperative IMDC criteria abnormalities, respectively. In multivariate analysis, patients with normal Hb, neutrophils, and Ca 2+ , both pre- and postoperatively, had an increase in overall survival (OS) compared to those with abnormal postoperative values. Hazard ratios (HR[95%CI]) for increased OS were 3.6[2.8-4.7], 2.1[1.7-2.7] and 3.5[1.5-43.1], respectively, compared to those with abnormal postoperative values. Furthermore, those with normal Hb, neutrophils, Plt, and Ca 2+ , both pre- and postoperatively, had an increase in cancer-specific survival (CSS) with HR of 3.3, 4.3, 8.0 and 5.7 (p<0.05),indicating a significantly higher CSS probability than patients with abnormal postoperative values. Conclusions: Abnormal IMDC laboratory criteria are frequently found in nmRCC, especially anemia, and most normalize after surgery. Finding abnormal IMDC laboratory criteria post-surgery is associated with decreased CSS and OS. This knowledge may be useful in stratifying patients for intensified monitoring or for future adjuvant therapy clinical trials.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (13)
Caio Vínicius Suartz
Université Laval, Quebec City, QC, Canada
Rodney H Breau
Ottawa Hospital Research Institute, Ottawa, ON, Canada
Kaleem Sulliman Atchia
Université Laval, Quebec City, QC, Canada
Camilla Tajzler
McGill University Health Center- Research Institute/Center for Innovative Medicine, Montréal, QC, Canada
Ranjeeta Mallick
Ottawa Hospital Research Institute, Ottawa
Daniel Yick Chin Heng
Department of Medical Oncology, Arthur JE Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB, Canada
Georg A. Bjarnason
Sunnybrook Odette Cancer Centre, Toronto, ON, Canada
Aly-Khan A. Lalani
Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada
Bimal Bhindi
Southern Alberta Institute of Urology, Calgary, AB, Canada
Lori Wood
Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada
Naveen S. Basappa
Simon Tanguay
McGill University Health Centre, Montréal, QC, Canada
Frederic Pouliot
CHU de Québec-Université Laval Research Center, Quebec City, QC, Canada